ReviewBrain sciences2022
Current Clinical Trials in Traumatic Brain Injury.
Review in Brain sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- The effect of methylphenidate and amantadine co-administration on functional outcome of patients with blunt traumatic brain injury: A randomized controlled trial.Acta neurologica Belgica · 2025Trial
- Pathway-level proteomics identifies subcellular trafficking dysregulation as a molecular signature in severe traumatic brain injury.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Article
- Review
- Comparing Acute and 1-Year Outcomes Between Fall- and Motor Vehicle-Related Traumatic Brain Injury: A NIDILRR TBI Model Systems Study.Neurology · 2026Article
- Dysregulation of Rho-Associated Coiled-Coil Protein Kinase1 Depletes Neural Stem Cell Pool and Impairs Hippocampal Neurogenesis After Traumatic Brain Injury.Cell proliferation · 2026Article
- The normative modelling framework for traumatic brain injury.Brain : a journal of neurology · 2025Review
- Oral Supplementation of n-3 Polyunsaturated Fatty Acids (n-3-PUFA) Can Prevent TBI-Induced Visual, Motor, and Emotional Deficits in Mice.Molecular neurobiology · 2025Article
- Claudin-1 impairs blood-brain barrier by downregulating endothelial junctional proteins in traumatic brain injury.Tissue barriers · 2025Article
- Role of damage-associated molecular patterns in the pathogenesis and therapeutics of traumatic brain injury.Burns & trauma · 2025Review
- The vestibular outcomes in non-blast related traumatic brain injury and the role of severity, aetiology and gender: a scoping review.Frontiers in neurology · 2025Review
- Traumatic brain injury promotes neurogenesis at the cost of astrogliogenesis in the adult hippocampus of male mice.Nature communications · 2024Article
- Neurotrauma-From Injury to Repair: Clinical Perspectives, Cellular Mechanisms and Promoting Regeneration of the Injured Brain and Spinal Cord.Biomedicines · 2024Review
- Vepoloxamer improves functional recovery in rat after traumatic brain injury: A dose-response and therapeutic window study.Neurochemistry international · 2024Article
- Editorial: New insights and perspectives on traumatic brain injury: integration, translation and multidisciplinary approaches.Frontiers in neurology · 2024Article
- Neurological manifestations of encephalitic alphaviruses, traumatic brain injuries, and organophosphorus nerve agent exposure.Frontiers in neuroscience · 2024Review
- Article
- Traumatic Brain Injury Outcomes After Recreational Cannabis Use.Neuropsychiatric disease and treatment · 2024Article
- Fluid-Based Protein Biomarkers in Traumatic Brain Injury: The View from the Bedside.International journal of molecular sciences · 2023Review
- Therapy of traumatic brain injury by modern agents and traditional Chinese medicine.Chinese medicine · 2023Review
- Research progress on pleiotropic neuroprotective drugs for traumatic brain injury.Frontiers in pharmacology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Traumatic brain injury (TBI) is one of the leading causes of morbidity, disability and mortality across all age groups globally. Currently, only palliative treatments exist, but these are suboptimal and do little to combat the progressive damage to the brain that occurs after a TBI. However, multiple experimental treatments are currently available that target the primary and secondary biochemical and cellular changes that occur after a TBI. Some of these drugs have progressed to clinical trials and are currently being evaluated for their therapeutic benefits in TBI patients. The aim of this study was to identify which drugs are currently being evaluated in clinical trials for TBI. A search of ClinicalTrials.gov was performed on 3 December 2021 and all clinical trials that mentioned "TBI" OR "traumatic brain injury" AND "drug" were searched, revealing 362 registered trials. Of the trials, 46 were excluded due to the drug not being mentioned, leaving 138 that were completed and 116 that were withdrawn. Although the studies included 267,298 TBI patients, the average number of patients per study was 865 with a range of 5-200,000. Of the completed studies, 125 different drugs were tested in TBI patients but only 7 drugs were used in more than three studies, including amantadine, botulinum toxin A and tranexamic acid (TXA). However, previous clinical studies using these seven drugs showed variable results. The current study concludes that clinical trials in TBI have to be carefully conducted so as to reduce variability across studies, since the severity of TBI and timing of therapeutic interventions were key aspects of trial success.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.